Sign in
CompletedPhase 2

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

Key facts

Who runs it
TWi Biotechnology, Inc.
Where
Anaheim, Atlanta, Bentonville, Canoga Park, Chicago, Decatur, Glen Oaks, League City, Miami, Miami Gardens, Monroe, Orlando, Pompano Beach, Richardson, Savannah, Sherman Oaks, St. Petersburg, and Torrance, United StatesSee the 18 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
93 people enrolled
Started
28 Mar 2024
Ended
6 Oct 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NORA520 Dose 1
  • NORA520 Dose 2
  • Placebo
Record updated
31 July 2026

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Are willing and able to provide signed informed consent to participate in the study and to comply with all study procedures and scheduled visits
  • Are an adult female between 18 and 45 years of age, inclusive
  • Have either ceased lactating at Screening, or if still lactating or actively breastfeeding at Screening, agree to temporarily cease giving breastmilk to their infant(s) from just prior to first dose of study drug on Day 1 through Day 14
  • Have a negative pregnancy test at Screening and Day 1 (prior to dosing)
  • Have had a depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery
  • Are ≤9 months postpartum at Screening

Who cannot take part

  • Have had recorded treatment failure of ≥2 different antidepressant classes (e.g., SSRI, SNRI) in the current or previous episode
  • Are currently experiencing active psychosis per Investigator assessment, or are taking typical or atypical antipsychotic medication
  • Have a history or current diagnosis or current treatment of bipolar disorder, schizophrenia, or schizoaffective disorder
  • Have a history of suicidal behavior within 2 years
  • Have a history or current diagnosis of sleep apnea or narcolepsy

Where in United States

  • Advanced Research CenterAnaheim, United States
  • Cenexel Clinical ResearchAtlanta, United States
  • Pillar Clinical ResearchBentonville, United States
  • Alliance Research InstituteCanoga Park, United States
  • Insight Hospital and Medical Center ChicagoChicago, United States
  • CenExel Clinical ResearchDecatur, United States
  • Zucker Hillside HospitalGlen Oaks, United States
  • Maximos Ob/GynLeague City, United States
  • MedOne Clinical ResearchMiami, United States
  • Meridian International Research, IncMiami Gardens, United States
  • Monroe Biomedical ResearchMonroe, United States
  • Combined ResearchOrlando, United States
  • Clinical Research Center of FloridaPompano Beach, United States
  • Pillar Clinical ResearcRichardson, United States
  • CenExel Clinical ResearchSavannah, United States
  • Cenexel Clinical ResearchSherman Oaks, United States
  • GCP ResearchSt. Petersburg, United States
  • Cenexel Clinical ResearchTorrance, United States

About the trial

What the trial wants to find out

The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine:

Read full original descriptionShow less

* How well NORA520 is tolerated and what side effects it may cause * If NORA520 reduces depressive symptoms in subjects with severe PPD * The amount of NORA520 in the blood at various times after taking the study drug; this provides information that helps determine how often NORA520 should be taken * In a subset of subjects, the amount of NORA520 in breastmilk at various times after taking it to determine if and how much NORA520 can pass into breastmilk Participate in this study will be randomly assigned to one of 3 different groups. All subjects will take the study drug for 3 days.

The 3 groups in the trial

  • NORA520 Tablets Dose 1Treatment being tested

    Treatment: NORA520 Dose 1

  • NORA520 Tablets Dose 2Treatment being tested

    Treatment: NORA520 Dose 2

  • Placebo TabletsPlacebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression
Record updated
31 July 2026